GlaxoSmithKline plc (LON:GSK) insider Dominic Redfern acquired 8 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were bought at an average cost of GBX 1,519 ($19.78) per share, with a total value of £121.52 ($158.25).
GlaxoSmithKline plc (GSK) traded down 0.40% on Thursday, hitting GBX 1483.50. The company had a trading volume of 6,597,200 shares. The firm has a 50-day moving average price of GBX 1,598.34 and a 200-day moving average price of GBX 1,623.98. The firm’s market capitalization is GBX 72.51 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56.
The firm also recently disclosed a dividend, which will be paid on Thursday, October 12th. Investors of record on Thursday, August 10th will be paid a GBX 19 ($0.25) dividend. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.
WARNING: “Insider Buying: GlaxoSmithKline plc (LON:GSK) Insider Purchases 8 Shares of Stock” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/2798583/insider-buying-glaxosmithkline-plc-longsk-insider-purchases-8-shares-of-stock.html.
A number of research analysts have issued reports on GSK shares. Barclays PLC reissued an “equal weight” rating and set a GBX 1,550 ($20.18) price objective on shares of GlaxoSmithKline plc in a report on Wednesday, April 12th. Deutsche Bank AG reissued a “hold” rating and set a GBX 1,720 ($22.40) price objective on shares of GlaxoSmithKline plc in a report on Wednesday, April 12th. J P Morgan Chase & Co reissued a “neutral” rating and set a GBX 1,670 ($21.75) price objective on shares of GlaxoSmithKline plc in a report on Tuesday, April 18th. Jefferies Group LLC cut their price objective on GlaxoSmithKline plc from GBX 1,850 ($24.09) to GBX 1,800 ($23.44) and set a “buy” rating for the company in a report on Thursday, April 20th. Finally, Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline plc in a report on Friday, April 21st. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the stock. GlaxoSmithKline plc presently has a consensus rating of “Hold” and a consensus target price of GBX 1,724 ($22.45).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.